Mylan, Pfizer settle patent suit on generic Detrol LA

Fri Sep 7, 2012 5:35pm IST

Stocks

   

(Reuters) - Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.

Mylan can start selling its generic versions of Pfizer's drug from January 1, 2014, or earlier under some limited circumstances, but not after March 1, 2014, if the U.S. Food and Drug Administration approves.

Terms of the settlement are subject to review by the Federal Trade Commission and the U.S. Department of Justice, and other details are confidential, Mylan said.

The settlement with Mylan comes days after Pfizer resolved a similar dispute with Impax Laboratories Inc late last month.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Akshay Lodaya)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Market Eye

REUTERS SHOWCASE

Bullish on Equities

Bullish on Equities

Bullish on Indian equities, but gains seen 'less sharp'- Goldman Sachs  Full Article 

Streamlining Operations

Jet Streamlines

Jet Airways chairman says looking to restructure debts, talking to bankers  Full Article 

Political Economy

Political Economy

Analysis - Watch what markets don't do as world politics turns nasty   Full Article 

Photo

Honda's India Thrust

Honda's India unit to account for 25 pct of Asia Pacific sales by March 2017 - exec   Full Article 

Short of Expectations

Short of Expectations

Apple revenue lags Street's view despite strong China growth  Full Article 

Mircosoft Results

Microsoft Results

Microsoft revenue rises, profit falls as Nokia absorbed  Full Article 

Relief For Sahara

Relief For Sahara

Supreme Court could allow Sahara boss to conduct asset sale talks, company says.  Full Article 

Photo

Food Scandal

Five held in China food scandal probe, including head of Shanghai Husi Food   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage